Levy Adam D., CFO of Acrivon Therapeutics ($ACRV), made one open market purchase of common shares worth about $15,000 in the last year. His most recent buy was on January 14, 2026. This ranks him 4,043rd among nearly 5,000 insiders by purchase amount, below the average of $1.46 million across about 3.3 transactions per insider. He reported no open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 1, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Levy Adam D. | Chief Financial Officer | A | Stock Option (Right to Buy) | 132925 | $0.00 | 132,925.0000 | 38,560,464 | 9999.99% | 0.34% |
| Jan. 14, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Levy Adam D. | Chief Financial Officer | P | Common Stock | 8832 | $1.70 | 20,983.0000 | 38,560,464 | 72.69% | 0.02% |
| Aug. 1, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Levy Adam D. | Chief Financial Officer | F | Common Stock | 1164 | $1.26 | 12,151.0000 | 33,791,817 | 8.74% | 0.00% |
| April 1, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Levy Adam D. | Chief Financial Officer | A | Stock Option (Right to Buy) | 35209 | $0.00 | 35,209.0000 | 33,791,817 | 9999.99% | 0.10% |